ROCKVILLE, MD - MaxCyte Inc. (NASDAQ: MXCT; LSE: MXCT), a company specializing in cell-engineering technologies for cell therapeutics and research, reported that John Johnston, a Non-Executive Director, exercised options over 3,000 shares of common stock on Sunday. Following the exercise, Johnston sold the shares at prices ranging from $3.995 to $4.060 per share on the Nasdaq stock exchange.
Johnston's transaction was conducted under a pre-arranged trading plan known as Rule 10b5-1, which was adopted on December 19, 2023, and pertains to the sale of shares acquired from the exercise of options that will expire on July 18, 2028. The exercise price for the options was $2.932 per share.
After the sale, Johnston's holding in the company amounts to 120,583 shares of common stock, which represents 0.1% of the issued stock capital. Additionally, he still holds 174,918 options over common stock and 21,367 restricted stock units.
The sale of shares by Johnston represents approximately 0.9% of his total equity and option holdings in MaxCyte's stock capital. The company has stated that the new shares of common stock were issued pursuant to its block admission facility.
MaxCyte's ExPERT platform, based on Flow Electroporation technology, supports the development and commercialization of cell-based therapies. The platform includes a range of instruments and software protocols, backed by a global intellectual property portfolio.
The information for this report is based on a press release statement from MaxCyte, Inc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.